Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

John G Ullman & Associates Inc. made a hefty bet on Regeneron Pharmaceuticals, upping their stake by a whopping 94%, now ...